Intercept Pharmaceuticals
Presença
Eles estão dentro:
- Holding50%
- Biotecnologia50%
Fusão, aquisição e financiamento envolvendo Genextra.
- Advanz Pharma has announced the acquisition of Intercept Pharmaceuticals (publicado em 6 de maio de 2022).
Executivos
Veja o organograma con seus 27 executivos principais
Biografias mais buscadas da Intercept Pharmaceuticals
- Jerome Durso, Director, President and Chief Executive Officer
- Nancy Miller-Rich, Director
- Luca Benatti, Director
Criar um alerta
para seguir os movimentos de executivos da Intercept Pharmaceuticals.
Biotecnologia
Genextra possui 2.284 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Karius acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 3 de maio de 2024).
- Transcarent acaba de anunciar uma arrecadação de fundos de 126 milhões de dólares. (publicado em 2 de maio de 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (publicado em 2 de maio de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Intercept Pharmaceuticals
- Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update | Intercept Pharmaceuticals, Inc.
- Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022 | Intercept Pharmaceuticals, Inc.
- Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA) | Intercept Pharmaceuticals, Inc.
- Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S. | Intercept Pharmaceuticals, Inc.
- Intercept Announces PBC Data Presentations at The International Liver Congress™ 2022 | Intercept Pharmaceuticals, Inc.
- Intercept Provides Update on NASH Regulatory Timeline | Intercept Pharmaceuticals, Inc.
- Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC | Intercept Pharmaceuticals, Inc.
- Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis | Intercept Pharmaceuticals, Inc.
- Intercept Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update | Intercept Pharmaceuticals, Inc.
- Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments | Intercept Pharmaceuticals, Inc.
- View more press releases Close
Redes sociais sobre Intercept Pharmaceuticals
- Intercept Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Intercept Pharmaceuticals na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Jerome Durso 
Ligue para a Intercept Pharmaceuticals em +1 646...
